CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit broad populations of cancer patients and others diseases, today announced that management will present the company’s pipeline, platform and business strategy at the Jefferies Healthcare Conference and the HC Wainwright Global Investment Conference, details of which are set out below.
Conference: Jefferies Healthcare Conference
Format: fireside chat with moderated Q&A
Presenters: Ben Zeskind, Ph.D., Chief Executive Officer and Brett Hall, Ph.D., Scientific Director
Date: June 8, 2022
Time: 2:00 p.m. – 2:25 p.m. ET in Lane 3
Conference: HC Wainwright Global Investment Conference
Format: Company Presentation
Presenters: Brett Hall, Ph.D., Scientific Director and Biren Amin, Chief Financial Officer
Date: On request from May 24 to 26, 2022
The Jefferies presentation will be webcast live and archived for 30 days at https://wsw.com/webcast/jeff240/imrx/1869600, and the HC Wainwright presentation will be available on demand and archived for 30 days at https:/ /journey.ct.events/view/3c2af387-6a8b-442b-82f7-4db414821c21.
About Immuneering Corporation
Immuneering aims to improve patient outcomes by advancing a unique pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Immuneering has over a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, Immuneering’s independent disease discovery platform enables the company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) a new chemistry. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual MEK inhibitor that further disrupts KSR to modulate MAPK pathway signaling dynamics. Specifically, it is designed to induce a deep cyclical inhibition that deprives tumor cells of the sustained proliferative signaling necessary for rapid growth, while providing a rate and moderate level of signaling sufficient to spare healthy cells. IMM-1-104 is being developed to treat advanced solid tumors in patients with RAS mutations, and is translationally guided by Immuneering’s proprietary human-aligned 3D tumor modeling platform combined with the patient-aligned bioinformatics. In addition to IMM-1-104, Immuneering is evaluating its MEK-io product candidate, IMM-6-415, in IND-enabling studies, and has five other discovery-stage oncology programs that are designed to target the components of the MAPK or mTOR pathway, as well as two neuroscience programs in the discovery phase.
This press release includes certain information that contains “forward-looking statements”, including, without limitation, statements regarding Immuneering’s expectations regarding the adequacy of Immuneering’s cash, cash equivalents and marketable securities. , its full-year GAAP operating expenses for 2022, the treatment potential of IMM-1-104 and IMM-6-415, the timing of IND submission and the start of clinical trials for IMM-1-104 and IMM-6-415, and Immuneering’s ability to advance its pipeline and further diversify its portfolio and advance its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including but not limited to target discovery, target validation, compound identification lead, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are more fully described in the section titled “Risk Factors” in Immuneering’s most recent Form 10-Q filed with the United States Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no obligation to update such information except as required by applicable law.
Rebecca Kusko, Ph.D.
Susan A. Noonan
SA Noonan Communications